### Perspectives

**A Novel Look into Estrogen Receptor–Negative Breast Cancer Prevention with the Natural, Multifunctional Signal Transduction Inhibitor Deguelin.** Jennifer M. Rodenberg and Powel H. Brown ........................................................................................................................................... 915

*Perspective on Murillo et al., p. 942*

**Oral Cancer Prevention Advances with a Translational Trial of Green Tea.** Dong M. Shin .................. 919

*Perspective on Tsao et al., p. 931*

### Review

**Convergence of Hormones, Inflammation, and Energy-Related Factors: A Novel Pathway of Cancer Etiology.** Martha L. Slattery and F.A. Fitzpatrick ........................................................................................................ 922

### Research Articles

**Phase II Randomized, Placebo-Controlled Trial of Green Tea Extract in Patients with High-Risk Oral Premalignant Lesions.** Anne S. Tsao, Diane Liu, Jack Martin, Xi-ming Tang, J. Jack Lee, Adel K. El-Naggar, Ignacio Wistuba, Kirk S. Culotta, Li Mao, Ann Gillenwater, Yuko M. Sagesaka, Waaun K. Hong, and Vassiliki Papadimitrakopoulou ........................................................................................................ 931

**Deguelin Inhibits Growth of Breast Cancer Cells by Modulating the Expression of Key Members of the Wnt Signaling Pathway.** Genoveva Murillo, Xinjian Peng, Karen E.O. Torres, and Rajendra G. Mehta .................................................................................................................................... 942

**Chemopreventive Efficacy of Naproxen and Nitric Oxide–naproxen in Rodent Models of Colon, Urinary Bladder, and Mammary Cancers.** Vernon E. Steele, Chinthalapally V. Rao, Yuting Zhang, Jagan Patlolla, Daniel Boring, Levy Kopelovich, M. Margaret Juliana, Clinton J. Grubbs, and Ronald A. Lubet ........................................................................................................................................ 951


**Effect of Orally Administered Bovine Lactoferrin on the Growth of Adenomatous Colorectal Polyps in a Randomized, Placebo-Controlled Clinical Trial.** Takahiro Kozu, Gen Inunuma, Yasuo Ohashi, Yutaka Saito, Takayuki Akasu, Daizo Saito, David B. Alexander, Masaaki Iigo, Tadao Kakizoe, and Hiroyuki Tsuda ........................................................................................................................................ 975

**Identification of Actively Translated mRNA Transcripts in a Rat Model of Early-Stage Colon Carcinogenesis.** Laurie A. Davidson, Naisyin Wang, Ivan Ivanov, Jennifer Goldsby, Joanne R. Lupton, and Robert S. Chapkin ........................................................................................................................................ 984

### Meeting Report

**Conference Report: Seventh Annual AACR International Conference on Frontiers in Cancer Prevention Research.** Powel H. Brown, Jaye L. Viner, Abenaa Brevster, Carolyn J. Heckman, Stephen Hursting, Karen Johnson, and Jenny T. Mao ........................................................................................................................................... 995
About the Cover

The cover figure depicts proposed mechanisms of action of the promising natural preventive agent deguelin. Previous work has demonstrated that deguelin inhibits the phosphatidylinositol 3-kinase (PI3K)/AKT and nuclear factor kappa B (NF-κB) signaling pathways in regulating gene expression (left side). Now, novel findings reported in this issue of the journal demonstrate that deguelin also regulates the wnt/β-catenin pathway (right side) in ER-negative breast cancer cells. Deguelin inhibited both ER-positive and -negative breast-cancer cell growth, but most strongly in ER-negative cells, causing a cell-cycle blockade and inducing apoptosis. Deguelin joins only a small group of agents shown to inhibit the growth of ER-negative breast cancer cell lines. See articles by Murillo et al. (beginning on page 942) and Rodenberg and Brown (beginning on page 915) for more information.